Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. New clinical trial format may boost cancer drug development

    Headlines

    Thu, 17 Apr 2014

    of patients so the traditional method of clinical trial design is too expensive, time-consuming and inefficient. AstraZeneca ( AZN ) will supply up to twelve experimental drugs that will be given to patients who do not show one of twenty-one

  2. New kind of trial aims to speed cancer drug development

    Headlines

    Wed, 16 Apr 2014

    * AstraZeneca , Pfizer, UK charity link in multi-drug trial

  3. UPDATE 2-Danske Bank fined by Nasdaq OMX over AstraZeneca share trading

    Headlines

    Wed, 16 Apr 2014

    * Danske Bank to pay 500,000 SEK for breaching trading rules

  4. AstraZeneca India unit sets floor price for stock delisting

    Headlines

    Fri, 11 Apr 2014

    April 11 (Reuters) - AstraZeneca Pharma India Ltd, a unit of British drugmaker AstraZeneca Plc , said on Friday the floor price for its delisting from the Indian stock exchanges had been set at 854.1 rupees a share.

  5. The Sector Is Fairly Valued, but These Stocks Are Not

    Video Reports

    Thu, 10 Apr 2014

    it's a great place to be, but from a valuation perspective a couple names we're concerned about are [TICKER:AZN] AstraZeneca and [TICKER:BAYRY] Bayer. And then when we flip to the other side, names we think are undervalued, really Sanofi

    Astrazeneca found at 0:33

    but from a valuation perspective a couple names we're concerned about are [TICKER:AZN] AstraZeneca and [TICKER:BAYRY] Bayer. And then when we flip to the other side, names we think are undervalued, really Sanofi comes to the top
  6. Sell Ranbaxy And Buy AstraZeneca : Good Chance Nexium Generic Launch Delayed

    Headlines

    Sat, 5 Apr 2014

    expected in May 27 2014 (as per settlement agreement with AstraZeneca ( AZN ) ). In 2013, Nexium generated $2.1b in annual ..... able to launch Nexium Generics timely and in that case AstraZeneca would be able to restore their brand exclusivity for

  7. After Bristol Myers' Bydureon Success, The Next Step Is Sustained Release Insulin

    Headlines

    Wed, 2 Apr 2014

    companies involved in producing these products include, Eli Lilly ( LLY ), Merck ( MRK ), P&G, Novartis ( NVS ), AstraZeneca ( AZN ), Sanofi-Aventis ( SNY ), Allergan ( AGN ) and Bausch & Lomb. Here's a quick rundown. Sustained Release

  8. AstraZeneca digs into new Cambridge home with MRC drug deal

    Headlines

    Sun, 30 Mar 2014

    * AstraZeneca moving global HQ and R&D to Cambridge by 2016

  9. Makings of a Wide Moat in Diabetes Care

    Headlines

    Fri, 28 Mar 2014

    next decade, we project the key GLP-1a will include AstraZeneca 's AZN Byetta/Bydureon, Novo's Victoza, Sanofi's ..... project the key drugs will be Merck 's MRK Januiva, AstraZeneca 's Onglyza, Eli Lilly's Trajenta, Novartis ' NVS

  10. AstraZeneca's New Diabetes Drug May Also Combat Alzheimer's Disease

    Headlines

    Thu, 27 Mar 2014

    By Glen S. Woods: A relatively new diabetes drug, Symlin (pramlintide), developed by AstraZeneca 's ( AZN ) Amylin Pharmaceuticals has been found to combat a major component of Alzheimer's disease ( AD ) and may offer a new

« Prev12345Next »
Content Partners